Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Toronto (May 11, 2015) – Women with luminal A subtype breast cancer – and particularly those older than 60 – may not need radiation treatment if they are already taking hormone therapy, shows clinical research led by radiation oncologists at the Princess Margaret Cancer Centre published online today in the Journal of Clinical Oncology.
The findings potentially advance delivery of personalized cancer medicine for up to 25% of women diagnosed with breast cancer in North America every year, say co-principal investigators Dr. Fei-Fei Liu, Chief, Radiation Medicine, and Dr. Anthony Fyles, staff radiation oncologist. Dr. Liu is Chair, Department of Radiation Oncology, University of Toronto, where Dr. Fyles is also a Professor. In Ontario alone, they estimate, this could save the provincial health care system up to $3 million annually.
They stress, however: "For all other breast cancer subtypes, radiation therapy is definitely of benefit and the required treatment."
Drs. Liu and Fyles examined tumour specimens from participants in a prior randomized clinical trial who received either tamoxifen (hormone therapy) plus whole-breast radiation therapy, or only tamoxifen.
The research team analysed molecular biomarkers in these samples which were then classified into six subtypes. The results demonstrated that women in the luminal A subtype had the best outcome, with a 10-year risk for local relapse of 8 percent with tamoxifen alone versus 4.5 percent with both tamoxifen and radiation.
The relapse rate was even lower for luminal A patients older than 60 – 4.3 percent with tamoxifen alone, versus 6 percent with tamoxifen plus radiation.
"For luminal A women over 60, local breast radiation did not add benefit to their outcome," says Dr. Liu.
Luminal A is defined as ER-positive, PR-positive, HER2-negative and low Ki-67 (an indicator that breast cancer cells are slowly growing, dividing or proliferating).
Three years ago, based on these findings, which Dr. Liu presented at the American Association for Cancer Research annual meeting, the researchers recommended that a larger prospective clinical study was needed as the next step to validate that routine testing for Ki-67 should take place. That study is now under way.
"This prospective clinical study, under the auspices of the Ontario Clinical Oncology Group, is enrolling 500 participants over three years from 15 cancer centres across Canada," says Dr. Fyles, who is principal investigator for the Princess Margaret.
"Post-menopausal women aged 55 or older with luminal A subtype breast cancer who are interested in participating should ask their treating physician if they are eligible for this study."
The research published today was funded by the Canadian Institutes of Health Research and The Princess Margaret Cancer Foundation.
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. For more information, go to www.theprincessmargaret.ca.
Phone: 416 340 4636